EP0269712A4 - An der pathogenese einer hiv-infektion beteiligte peptide. - Google Patents

An der pathogenese einer hiv-infektion beteiligte peptide.

Info

Publication number
EP0269712A4
EP0269712A4 EP19870903968 EP87903968A EP0269712A4 EP 0269712 A4 EP0269712 A4 EP 0269712A4 EP 19870903968 EP19870903968 EP 19870903968 EP 87903968 A EP87903968 A EP 87903968A EP 0269712 A4 EP0269712 A4 EP 0269712A4
Authority
EP
European Patent Office
Prior art keywords
pathogenesis
hiv infection
peptides involved
peptides
involved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19870903968
Other languages
English (en)
French (fr)
Other versions
EP0269712A1 (de
Inventor
Richard A Fisher
Vicki L Sato
Kuzhalmannam L Ramachandran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GILBERT, WALTER
Biogen Inc
Original Assignee
Biogen NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen NV filed Critical Biogen NV
Publication of EP0269712A1 publication Critical patent/EP0269712A1/de
Publication of EP0269712A4 publication Critical patent/EP0269712A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP19870903968 1986-06-12 1987-06-09 An der pathogenese einer hiv-infektion beteiligte peptide. Withdrawn EP0269712A4 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87362186A 1986-06-12 1986-06-12
US873621 1986-06-12
US4193687A 1987-04-24 1987-04-24
US41936 1987-04-24

Publications (2)

Publication Number Publication Date
EP0269712A1 EP0269712A1 (de) 1988-06-08
EP0269712A4 true EP0269712A4 (de) 1990-06-26

Family

ID=26718709

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19870903968 Withdrawn EP0269712A4 (de) 1986-06-12 1987-06-09 An der pathogenese einer hiv-infektion beteiligte peptide.

Country Status (5)

Country Link
EP (1) EP0269712A4 (de)
JP (1) JPH01501547A (de)
AU (1) AU617088B2 (de)
NZ (1) NZ220653A (de)
WO (1) WO1987007616A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126399A (en) * 1986-04-30 1992-06-30 Board Of Regents, The University Of Texas System Methods and compositions for the preparation and use of site-directed immunologic reagents
EP0525828A3 (en) * 1986-08-01 1993-02-24 Repligen Corporation Recombinant polypeptides and their uses, including assay for aids virus
US5166050A (en) * 1986-08-20 1992-11-24 Bristol-Myers Squibb Company Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections
US5976541A (en) * 1988-01-26 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Potent peptide for stimulation of cytotoxic T lymphocytes specific for the HIV-1 envelope
NO881151L (no) * 1987-03-27 1988-09-28 Syntello Ab Syntetisk hiv-1-antigen.
FI872409A0 (fi) * 1987-05-29 1987-05-29 Labsystems Oy Foerfarande foer detektering av hiv-1 motkroppar.
AU621097B2 (en) * 1988-01-26 1992-03-05 United States of America, as represented by the Secretary, U.S. Department of Commerce, The A synthetic antigen evoking anti-hiv response
US5820865A (en) * 1988-01-26 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Method to induce cytotoxic T Lymphocytes specific for a broad array of HIV-1 isolates using hybrid synthetic peptides
CA1341285C (en) * 1988-02-12 2001-08-14 Chang Yi Wang Synthetic peptides for the detection of antibodies to hiv gp120 envelope protein for diagnosis of aids and pre-aids conditions and as vaccines
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
EP0339504A3 (de) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Menschliches immunoinsuffizientes Virus (HIV) env-codiertes Peptid, welches im Stande ist, die HIV hemmenden Antikörper bei Säugetieren hervorzurufen
US5562905A (en) * 1988-04-26 1996-10-08 E. I. Du Pont De Nemours And Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
KR900701836A (ko) * 1988-10-03 1990-12-04 라메쉬 엘. 라탄 신규 hiv 단백질 및 aids의 진단, 예방 또는 치료에 유용한 펩티드
DK0470184T3 (da) * 1989-04-25 1997-03-10 Tanox Biosystems Inc Specifikke antistoffer for det CD4-bindende domæne i HIV
US6309880B1 (en) * 1989-04-25 2001-10-30 Tanox, Inc. Antibodies specific for CD4-binding domain of HIV-1
GB8912496D0 (en) * 1989-05-31 1989-07-19 Medical Res Council Vaccines
US5346989A (en) * 1990-08-22 1994-09-13 Syntello Vaccine Development Kb Peptides for use in induction of T cell activation against HIV-1
WO1992005800A1 (en) * 1990-09-27 1992-04-16 Syntello Vaccin Development Kb Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
US5840313A (en) * 1990-09-27 1998-11-24 Syntello Vaccine Development Kb Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
CA2109961A1 (en) * 1991-06-03 1992-12-10 Anders Vahlne Peptides for use in induction of t cell activation against hiv-1
US5444044A (en) * 1992-03-26 1995-08-22 New York Blood Center Synthetic polypeptides as inhibitors of HIV-1
ES2053413T3 (es) * 1992-05-14 1997-11-16 Polymun Scient Immunbio Forsch Peptidos que inducen anticuerpos que neutralizan aislados de vih-1 geneticamente divergentes.
ATE258188T1 (de) 1992-08-27 2004-02-15 Deakin Res Ltd Retro-, inverso-, und retro-inverso synthetische peptidanaloge
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
FR2717081B1 (fr) * 1994-03-14 1996-06-21 Centre Nat Rech Scient Rétropeptides, anticorps dirigés contre ces derniers, et leurs utilisations pour la vaccination et le diagnostic in vitro.
EP0868196A4 (de) * 1995-10-20 2004-11-24 Univ Duke Synthetischer impfstoff zum schutz gegen eine infektion durch das humane immundefizienz virus
US6749856B1 (en) 1997-09-11 2004-06-15 The United States Of America, As Represented By The Department Of Health And Human Services Mucosal cytotoxic T lymphocyte responses
ES2245505T3 (es) * 1998-03-23 2006-01-01 Trimeris Inc. Metodos y composiciones para la sintesis de peptidos (t-20).
US6281331B1 (en) * 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
ATE508139T1 (de) * 2003-04-11 2011-05-15 Pasteur Institut Synthetische peptid-hiv-vakzine: das cbd-epitop als effizientes immunogen zur induktion hiv- neutralisierender antikörper
US20060205070A1 (en) * 2004-01-13 2006-09-14 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services HIV TEV compositions and methods of use
EP1714153A2 (de) * 2004-02-06 2006-10-25 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Von gp41 abgeleitetes polypeptid, das polypeptid enthaltende impfstoffzusammensetzung sowie verwendungen zur behandlung einer hiv-virusinfektion in einem individuum
WO2007039458A2 (en) * 2005-09-21 2007-04-12 Cytos Biotechnology Ag Hiv peptide conjugates and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986002383A1 (en) * 1984-10-18 1986-04-24 Institut Pasteur Envelope antigens of lymphadenopathy associated virus and their applications

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
GB8525615D0 (en) * 1985-10-17 1985-11-20 Hoffmann La Roche Polypeptides
US4772547A (en) * 1986-02-03 1988-09-20 Hoffmann-La Roche Inc. HTLV-III envelope peptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986002383A1 (en) * 1984-10-18 1986-04-24 Institut Pasteur Envelope antigens of lymphadenopathy associated virus and their applications

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bio/Technology, Vol. 3, October 1985, pages 905-909, TSE WEN CHANG et al.: "Detection of antibodies to human T-cell lymphotropic virus- III (HTLV-III) with an immunoassay employing a recombinant Escherichia Coli-derived viral antigenic peptide", whole document. *
Science, Vol. 231, March 28, 1986, pages 1556-1559, R.C. KENNEDY et al.: "Antiserum to a synthetic peptide recognized the HTLV-III envelope glycoprotein", whole document. *
See also references of WO8707616A1 *

Also Published As

Publication number Publication date
EP0269712A1 (de) 1988-06-08
AU617088B2 (en) 1991-11-21
NZ220653A (en) 1990-06-26
JPH01501547A (ja) 1989-06-01
WO1987007616A1 (en) 1987-12-17
AU7540487A (en) 1988-01-11

Similar Documents

Publication Publication Date Title
EP0269712A4 (de) An der pathogenese einer hiv-infektion beteiligte peptide.
FI873117A0 (fi) Hopvikbar ihaolig artikel.
FI880765A (fi) Foer engaongsanvaendning avsedd vaetskeabsorberande artikel.
DE3778287D1 (de) Peptidische zusammensetzung.
DE3774374D1 (de) Wundheilende zubereitungen.
NO873080D0 (no) Mikrobicid tilberedning.
DE3788408T2 (de) Immunverstärkung.
DE3774594D1 (de) Verbundkoerper.
FI880020A0 (fi) Vaesentigen ren cytotoxitet utloesande faktor.
NO864588D0 (no) Filterlegeme.
DE3671886D1 (de) Zusammengesetzter koerper.
NO874193D0 (no) Farmasoeytiske preparater.
DE3786301T2 (de) Kombinierter Impfstoff.
ES2015548B3 (es) Boton.
DE3766147D1 (de) Schleifkoerper.
DE3764163D1 (de) Schnalle.
EP0338092A4 (de) Anti-hiv-agens.
OA09308A (en) Anti-HIV agent.
ES2018552B3 (es) Articulo interengranable.
EP0266401A4 (de) Impfstoffe.
ES2014488B3 (es) Procedimiento de preparacion de mercaptoalcoholes.
NO875019D0 (no) Antikariogene preparater.
MX9203757A (es) Derivado de eritromicina y la preparacion y uso del mismo.
ZA878917B (en) 1-aryloxy-3-amino-2-propanols,the preparation and use thereof
TR23141A (tr) Oksodiazolon tuerevi bunun hazirlanma prosesi,ve bunu ihtiva eden herbisid

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19880219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GILBERT, WALTER

Owner name: BIOGEN, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 19900626

17Q First examination report despatched

Effective date: 19911004

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19920415

RIN1 Information on inventor provided before grant (corrected)

Inventor name: RAMACHANDRAN, KUZHALMANNAM, L.

Inventor name: SATO, VICKI, L.

Inventor name: FISHER, RICHARD, A.